Can't find this one recent one you speak of, but here is an oldie but a goodie from Baker-Young, with a target price of 35c at the low end.
http://actinogen.com.au/wp-content/uploads/2015/11/Baker-Young-Initiation-of-Coverage.pdf
"We initiate coverage of Actinogen with a BUY recommendation and we value ACW at $0.35 per share base case and $1.03 per share optimistic case using the probability weighted DCF methodology assuming successful Phase II trial results and an industry standard licensing transaction. Our target price of $0.35 sits in the low point of our valuation range".
Corporate Research Report OUT 27.9.16 PRICE TARGET 39 cents., page-3
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.06M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $38.46K | 1.555M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1610993 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 2045428 | 11 |
View Market Depth
| Last trade - 11.35am 07/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |